Quick Answer
Acumen Pharmaceuticals, Inc. reported Total Assets of $122.83 million for the year ending 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -48.6% in Total Assets from 2024 to 2025.
- This data is from Acumen Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $72.94 million | Q3 2021: $234.85 million | Q1 2022: $220.09 million | Q2 2022: $211.68 million | Q3 2022: $203.26 million | Q1 2023: $187.86 million | Q2 2023: $177.41 million | Q3 2023: $286.37 million | Q1 2024: $300.97 million | Q2 2024: $288.91 million | Q3 2024: $266.98 million | Q1 2025: $204.48 million | Q2 2025: $171.90 million | Q3 2025: $142.22 million.
- Over the full 6 years of available data (2020 to 2025), Acumen Pharmaceuticals, Inc.'s Total Assets has grown by 176.5%.
- Historical annual values: Fiscal year 2025: $122.83 million | Fiscal year 2024: $238.99 million | Fiscal year 2023: $310.13 million | Fiscal year 2022: $196.59 million | Fiscal year 2021: $230.33 million | Fiscal year 2020: $44.43 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: